The Significant Influence of the Neuroendocrine Component on the Survival of Patients with Gastric Carcinoma Characterized by Coexisting Exocrine and Neuroendocrine Components
Table 1
Clinicopathological features for all patients.
Variables
GAC with NE component
GAC without NE component
p value
GAC with NED (0<NE<30%)
MANEC (30≤NE≤70%)
NEC (70<NE<100%)
Total
Gender
Male
28
24
30
82
142
0.247
Female
4
5
4
13
48
Age (years)
≤60
15
12
16
43
100
0.241
>60
17
17
18
52
90
Location
Upper
19
15
18
52
86
0.127
Middle
2
8
8
18
31
Lower
11
6
8
25
73
Curvature
Lesser
16
8
14
38
91
0.194
Greater
1
3
5
9
37
Diameter (cm) (mean)
4.82
4.09
5.16
4.64
4.78
Lauren type
Intestinal
15
11
4
30
63
0.234
Diffuse
4
7
5
16
59
Mixed
11
8
3
22
47
pT stage
T1
3
5
1
9
27
0.062
T2
5
4
2
11
20
T3
17
14
26
57
85
T4
7
6
5
18
58
pN stage
N0
11
8
10
29
59
0.462
N1
5
7
5
17
46
N2
6
2
9
17
36
N3
10
12
10
32
49
pTNM stage
I
5
7
2
14
35
0.717
II
11
6
12
29
58
III
16
16
20
52
97
Synaptophysin
Negative
6
2
0
8
N/A
1+
26
15
14
55
2+
0
12
20
32
Chromogranin A
Negative
6
9
10
25
N/A
1+
26
14
14
54
2+
0
6
10
16
CD56
Negative
19
11
12
42
N/A
1+
6
4
5
15
2+
1
4
3
8
3+
0
5
6
11
Mitotic index (2 mm2) (mean)
35.67
29.50
49.38
37.71
Ki-67 () (mean)
56.00
55.44
57.70
56.21
Neoadjuvant therapy
No
31
25
34
90
179
0.856
Yes
1
1
3
5
11
Adjuvant therapy
No
10
6
15
31
45
0.074
Yes
18
22
18
59
141
Follow-up (month) (mean)
43.6
38.2
40.1
40.8
45.7
N/A: not applicable. The scoring system for IHC modified and used with permission by the Clinical and Laboratory Standards Institute (CLSI), document I/LA28-A2 [8].
